Blood sampling
BiologicalBlood sampling will be performed at 6 months after myocardial infarction to analyse diagnostic and prognostic biomarkers
NCT Number: NCT03070496
Ischemic heart disease is the leading cause of mortality with 7.2 million of death in industrialized countries (WHO data). Myocardial infarction corresponding to acute occlusion of a coronary artery is the most brutal form and the more severe ischemic myocardial disease. Every year in France, about 60,000 Myocardial infarctions hospitalized, 30,000 are diagnosed remotely and 30,000 are revealed by an inaugural sudden death. Although mortality from myocardial decreased by 30% over the past decade, the prognosis is pejorative and difficult to assess precisely. The management of the patient depends on these factors, and justifies an active search on these topics, including the mechanisms of the deleterious ventricular remodeling, myocardial inflammation, reperfusion injury which determines in particular the evolution to heart failure. Cohorts of patients with myocardial infarction are rare but can be very valuable by their clinical, laboratory and imaging well documented. They are the source of new hypotheses for research or interventions as well as the quality of care assessment tool.
The main objective of this project is to identify new markers: biological and imaging, treatment response and prognosis after acute myocardial infarction.
Secondary objectives of the HIBISCUS-STEMI cohort to establish a clinical database, completed by biological samples and by imaging data that can be used in the following areas:
* Descriptive epidemiology of myocardial infarction and myocardial reperfusion * Pharmacoepidemiology and treatments observatory: safety, efficacy, indication of treatment in real life, costs * Assessment of the long-term effect of the treatment on the occurrence of heart failure and sudden death * Quality of life and personal consequences, family, professional and social myocardial infarction * Research of new diagnostic and prognostic biomarkers * Research projects (e.g. risk of developing kidney failure or stroke in patients with myocardial infarction compared to the general population).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Hôpital Cardiovasculaire Louis Pradel, Bron, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Blood sampling will be performed at 6 months after myocardial infarction to analyse diagnostic and prognostic biomarkers
ECG will be performed at 6 months after myocardial infarction
MRI will be performed at 1month after myocardial infarction to analyse ventricular remodeling and reperfusion.
Patients will pass a quality of life questionnaire at 12 months after myocardial infarction
Time frame: Up to 3 years after myocardial infarction
Heart failure stage will be assessed thanks to the New York Heart Association (NYHA) classification
Time frame: 1 month after myocardial infarction
Infarct size will be measured on MRI
Time frame: H0 (admission in coronary angiography room)
Cardiac enzymes rate will be analysed in blood samples
Time frame: H4 (4 hours after reperfusion)
Cardiac enzymes rate will be analysed in blood samples
Time frame: H24 (24 hours after reperfusion)
Cardiac enzymes rate will be analysed in blood samples
Time frame: H48 (48 hours after reperfusion)
Cardiac enzymes rate will be analysed in blood samples
Time frame: 1 month after myocardial infarction
Cardiac enzymes rate will be analysed in blood samples
Time frame: 3 months after myocardial infarction
Cardiac enzymes rate will be analysed in blood samples
Time frame: 6 months after myocardial infarction
Cardiac enzymes rate will be analysed in blood samples
Time frame: 12 month after myocardial infarction
Cardiac enzymes rate will be analysed in blood samples
Time frame: 12 month after myocardial infarction
Patients' quality of life will be evaluated thanks to the EQ-5D questionnaire
Hospices Civils de Lyon
Other
CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in ST Elevation Myocardial Infarction
Acronym: HIBISCUS-STEMI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06945900
Cardiovascular Diseases, Heart Diseases
Winston-Salem, North Carolina, United States
View Trial DetailsNCT03677180
Acute Myocardial Infarction, Cardiogenic Shock
Birmingham, Alabama, United States
View Trial DetailsNCT04284995
Cardiovascular Diseases, Coronary Disease
Nieuwegein, CM, Netherlands
View Trial DetailsNCT07641231
Cardiovascular Diseases, Heart Diseases
Moscow, Select A State, Russia
View Trial Details